论文信息 - Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients - 字舞流文

Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients

Stanley J Tamaki | S. Asthana | S. Darmanis | M. Spitzer | K. Ansel | D. Erle | P. Woodruff | Diana M. Marquez | C. Calfee | M. Krummel | C. Langelier | S. Chak | A. Jauregui | Trine Line Hauge Okholm | Cassandra E. Burnett | P. Sinha | Kamir J. Hiam-Galvez | A. Ward | Sidney Carrillo | K. Kangelaris | C. Hendrickson | P. M. Sandoval | R. Ghale | A. Willmore | Raphael Lota | Viet Nguyen | Logan Pierce | Cole Shaw | Austin Sigman | Luz Torres Altamirano | I. Tenvooren | Sadeed Rashid | S. Ke | K. Yee | B. Samad | N. Rodriguez | G. Fragiadakis | S. Bhide | L. Lupin-Jimenez | Alexander Beagle | E. Tumurbaatar | Kristine Wong | Jeremy Giberson | T. Lea | Cathy Cai | Zachary Collins | Deanna Lee | Priya Prasad | Kevin Tang | C. Ye | A. Rao | Iliana Tenvooren | Yumiko Abe-Jones | Ana Gonzalez | Trine Line Hauge Okholm | Priscila Munoz Sandoval | Ravi Yumiko Saurabh Alexander Sharvari Cathy Maria Sidn Patel Abe-Jones Asthana Beagle Bhide Cai Cal | Ravi K Patel | Maria Calvo | Pat Glenn | Nishita Nigam | Vaibhav Upadhyay | Mingyue Zhou

[1] Mark S. Anderson,et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 , 2021, Science Translational Medicine.

[2] R. Nussbaum,et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 , 2021, Science immunology.

[3] N. Skoetz,et al. Systemic corticosteroids for the treatment of COVID-19. , 2021, The Cochrane database of systematic reviews.

[4] Jordan L. Metcalf,et al. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study , 2021, Science immunology.

[5] Peter J. Godolphin,et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. , 2021, JAMA.

[6] E. Wherry,et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.

[7] M. C. Muenker,et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19 , 2021, Nature Medicine.

[8] Steve B Jones,et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.

[9] J. Fountain,et al. Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids , 2021, American journal of respiratory and critical care medicine.

[10] I. Douglas,et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[11] C. Wolf,et al. Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.

[12] E. Wherry,et al. New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 , 2021, medRxiv.

[13] H. Qiu,et al. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype , 2020, Chest.

[14] Elizabeth B White,et al. Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[15] Chun Jimmie Ye,et al. Global Absence and Targeting of Protective Immune States in Severe COVID-19 , 2020, bioRxiv.

[16] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[17] Graham M Lord,et al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19 , 2020, Science Immunology.

[18] R. Nahass,et al. Impact of tocilizumab administration on mortality in severe COVID-19 , 2020, Scientific Reports.

[19] Li Yang,et al. COVID-19: immunopathogenesis and Immunotherapeutics , 2020, Signal Transduction and Targeted Therapy.

[20] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[21] Sasikanth Manne,et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[22] Pratik Sinha,et al. Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.

[23] R. Jiang,et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma , 2020, Journal for immunotherapy of cancer.

[24] Kamir J. Hiam,et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models , 2020, Nature Medicine.

[25] H. Maecker,et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis , 2020, medRxiv.

[26] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.

[27] M. Chiarini,et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[28] R. Trimble. COVID-19 Dashboard , 2020 .

[29] G. Nolan,et al. Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry , 2018, Nature Protocols.

[30] Eli R. Zunder,et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[31] W. Mitzner,et al. Foxp3+ Regulatory T Cells Promote Lung Epithelial Proliferation , 2014, Mucosal Immunology.

[32] L. King,et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. , 2013, American journal of respiratory cell and molecular biology.

[33] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[34] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[35] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .

[36] Cedric E. Ginestet. ggplot2: Elegant Graphics for Data Analysis , 2011 .